Asaf Danziger - 30 Jun 2025 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Director
Signature
Steven Robbins, as attorney in fact for Danziger, Asaf
Issuer symbol
NVCR
Transactions as of
30 Jun 2025
Net transactions value
+$12,603
Form type
4
Filing time
01 Jul 2025, 16:19:41 UTC
Previous filing
03 Jan 2025
Next filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Danziger Asaf Director C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE Steven Robbins, as attorney in fact for Danziger, Asaf 01 Jul 2025 0001654435

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $12,603 +833 +0.2% $15.13 416,473 30 Jun 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.